Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The approval makes Talzenna (talazoparib) the third PARP-blocking drug to be cleared by the FDA to treat prostate cancer.
Treatment with androgen receptor inhibitors was associated with a higher likelihood of falls and fractures.
The drug was previously approved for castration-resistant prostate cancer.
First targeted therapy may prolong survival of men with advanced prostate cancer.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
These men lived for a median of 30 months compared to 26 months for white men.
Androgen receptor blocker approved for cancer that progresses despite low testosterone levels.
Androgen receptor inhibitor now approved for both metastatic and nonmetastatic disease.
The American Society of Clinical Oncology has released new prostate cancer guidelines.
Xtandi and Erleada both prolonged the time to disease progression or death by about two years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.